SNRIs May Be More Tolerable Than SSRIs for Some Youth With Anxiety, OCD
Youth who are taking antidepressants in the class of serotonin reuptake inhibitors (SSRIs) for anxiety or obsessive compulsive disorder (OCD) are more likely to experience side effects that cause them to discontinue the medication than those taking serotonin-norepinephrine inhibitors (SNRIs), according to a report in theJournal of the American Academy of Child and Adolescent Psychiatry.SSRIs also appear to be more commonly associated with “activation syndrome”—a cluster of symptoms including restlessness, anxiety, and agitation.Both classes of antidepressants are commonly prescribed for young people with anxiety and OCD, although SSRIs have been shown to be more effective. There are few data on specific side effects that may cause children and teens to stop taking these medications; however, this analysis suggests that SNRIs may be an option for youth who experience adverse effects with SSRIs, wrote lead author Jeffrey A. Mills, Ph.D., of the University of Cincinnati School of Business and Jeffrey Shawn, M.D., of Cincinnati Children ’s Hospital.The researchers analyzed data on adverse reactions to SSRIs and SNRIs in 18 studies involving more than 2,600 children and teenagers under the age of 18 treated for anxiety or OCD. The studies compared the two classes of drugs with placebo. The SSRIs that were studied were fluoxetine, fluvoxamine, sertraline, and paroxetine; the SNRIs were venlafaxine, atomoxetine, and duloxetine.In the analysis looking at combi...
Publication date: November–December 2020Source: Heart &Lung, Volume 49, Issue 6Author(s): Linda Clements, Susan K. Frazier, Debra K. Moser, Terry A. Lennie, Misook L. Chung
Publication date: 1 January 2021Source: Personality and Individual Differences, Volume 168Author(s): Feizhong Zheng, Wenting Wu, Lijing Wang, Arlette J. Ngoubene-Atioky, Li Chen
Publication date: Available online 22 September 2020Source: International Journal of PsychophysiologyAuthor(s): Chiara Massullo, Giuseppe Alessio Carbone, Benedetto Farina, Angelo Panno, Cristina Capriotti, Marta Giacchini, Sérgio Machado, Henning Budde, Eric Murillo-Rodríguez, Claudio Imperatori
CONCLUSION: In a NHP ARS model, sargramostim administered starting at 48 h post-radiation was effective to improve survival, while beneficial hematological effects were observed with sargramostim initiated up to 120 h post exposure. PMID: 32960660 [PubMed - as supplied by publisher]
CONCLUSIONS: Under a real-life clinical practice setting, SSTS provides effective pain management and is easy to use for patients and nurses. PMID: 32959632 [PubMed - as supplied by publisher]
In 2019, before the pandemic hit, nearly 1 in 5 adults had depression and nearly 1 in 6 had anxiety, with dramatic increases seen in 2020.Medscape Medical News
Authors: Wong A, Keith C, Gregory H, Liew D Abstract COVID-19 brings with it unprecedented challenges in clinical management. An important component of care is the provision of safe and effective symptom control. Given the emerging literature reporting on the risk of QT prolongation and arrhythmias associated with COVID-19 disease and experimental therapies, we highlight some considerations for the prescribing of palliative care medications in this context. Based on the experience gained from palliative care referrals at our institution prior to and during the COVID-19 pandemic, and in collaboration with our clinic...
We report a case of using ketamine as a patient-controlled analgesia (PCA) for the treatment of CPS. A 58-year-old male with CPS presented with severe generalized body pain refractory to multiple pharmacological interventions. He was started on a basal infusion rate at 0.3 mg/kg/h with a ketamine PCA bolus of 10 mg with a 10-minute lockout period. Over the next 7 days, the basal infusion rate was titrated up to 2.1 mg/kg/h relative to the number of times the patient pressed the PCA. At the end of the trial, the patient reported 0/10 pain with lightheadedness on the first day being the only side ...
Publication date: November 2020Source: Epilepsy &Behavior, Volume 112Author(s): Mehri Salari, Masoud Etemadifar, Koroush Gharagozli, Koorosh Etemad, Farzad Ashrafi, Helia Ashourizadeh
Publication date: November 2020Source: Epilepsy &Behavior, Volume 112Author(s): Daniel Delev, Karlijn Hakvoort, Alexander Grote, Georg Neuloh, Hans Clusmann, Marec von Lehe